Blog Posts
July 7, 2023

COVID-19: A Disruptor and a Catalyst in Clinical Trials and the Future of Medicine

Blog Posts
July 7, 2023

COVID-19: A Disruptor and a Catalyst in Clinical Trials and the Future of Medicine

Author
Neneh Vannitamby, MD
Medical Writer

The global pandemic caused by COVID-19 has cast a profound impact on nearly every aspect of our lives. Its effects on health, economics, education, and social structures are apparent, but there are less visible but equally significant impacts too. One such sphere is that of clinical trials –the pivotal groundwork for the future of medicine. With the pandemic causing unprecedented disruptions, we also see an unexpected catalyst for change, potentially reshaping the biotechnology industry as we know it.

An Unseen Complication

The first and foremost effect of COVID-19 on clinical trials was in their operation. Clinical trials are typically conducted in specialized facilities, requiring participants to make regular visits for monitoring and administration of investigational treatments. COVID-19, however, threw a wrench into this traditional model. With lockdowns and social distancing measures in place, both patients and researchers were unable to perform these necessary steps.

Trials were delayed or cancelled, resulting in significant setbacks in the development of new therapies. A study conducted by the Journal of the American Medical Association found that, in the first few months of the pandemic, over 80% of non-COVID clinical trials were paused or halted. These disruptions meant not just slower progress, but also wasted resources and a potential decrease in the reliability of results due to interrupted treatment schedules.

The Rise of Remote Trials 

However, with every challenge comes an opportunity. The pandemic spurred the adoption of decentralized trials, also known as remote or virtual trials. These trials utilize digital health technologies, like wearable sensors and telemedicine, to collect data remotely and maintain participant engagement.

Patients can participate from their homes, with medications being mailed to them and medical consultations happening over video calls. With its promise of greater accessibility and convenience for patients, this approach can potentially increase the diversity and inclusivity of clinical trials – a long-standing issue in this field. See our article on Diversity in Clinical Trials about this topic.

Impact on the Biotech Industry

The biotechnology industry, at the forefront of innovative therapies, was particularly affected by these changes. Companies had to pivot rapidly to integrate new technologies and redesign trials to meet the needs of the remote model. This was not a simple feat – it required overcoming regulatory hurdles, implementing new technologies, and ensuring data integrity and patient safety.

Despite the initial challenges, many biotech companies are finding the remote approach to be cost-effective and efficient. This shift has been largely facilitated by advanced AI algorithms that aid in patient recruitment, remote monitoring, and data analysis. The use of AI and digital technology in clinical trials is revolutionizing the biotech industry, allowing for faster and more efficient trials, even in the face of global challenges like a pandemic.

Future of Medicine: A Revolution Triggered

COVID-19 has, without a doubt, disrupted the traditional path of clinical trials. Yet, it has also sparked a revolution that might well change the face of clinical research and medicine.

The shift towards decentralized trials, coupled with the use of AI and digital technologies, has implications far beyond the pandemic. It has the potential to make clinical trials more patient-centric, more efficient, and more inclusive, transforming the very landscape of drug development.

The future of medicine might see a more fluid, dynamic approach to trials. We could have adaptive trial designs that evolve with emerging data, powered by AI algorithms. Real-world data could play a larger role, complementing controlled trial data and giving us a more comprehensive understanding of drug effects.

The way we perceive the pandemic's impact on clinical trials is, therefore, a matter of perspective. While it has indeed caused unprecedented disruptions, it has also pushed the boundaries of innovation and has set in motion changes that could revolutionize the future of medicine and the biotech industry. In a sense, we can view COVID-19 not just as a disruptor, but also as a powerful catalyst for change.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.